Tuberculosisﾠ(TB) is an infectious disease usually caused by Mycobacteriumﾠtuberculosisﾠ(MTB) bacteria.ﾠTuberculosisﾠgenerally affects the lungs, but can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latentﾠtuberculosis. LPI (LP Information)' newest research report, the ﾓTuberculosis Therapeutics Industry Forecastﾔ looks at past sales and reviews total world Tuberculosis Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Tuberculosis Therapeutics sales for 2023 through 2029. With Tuberculosis Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tuberculosis Therapeutics industry. This Insight Report provides a comprehensive analysis of the global Tuberculosis Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tuberculosis Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firmsﾒ unique position in an accelerating global Tuberculosis Therapeutics market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tuberculosis Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tuberculosis Therapeutics. The global Tuberculosis Therapeutics market size is projected to grow from US$ 821.8 million in 2022 to US$ 1011.3 million in 2029; it is expected to grow at a CAGR of 3.0% from 2023 to 2029. United States market for Tuberculosis Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. China market for Tuberculosis Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. Europe market for Tuberculosis Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. Global key Tuberculosis Therapeutics players cover Aventis Pharmaceuticals, Sanofi -Aventis, Versapharma Incorporated, Sigma Pharmaceutical Pty, Novartis AG, Hoffmann-La Roche and Bayer Health Care, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022. This report presents a comprehensive overview, market shares, and growth opportunities of Tuberculosis Therapeutics market by product type, application, key players and key regions and countries. Market Segmentation: Segmentation by type Isoniazid Rifampin Pyrazinamide Hydrazine Derivatives Miscellaneous Anti-Tubercular Drugs Ethambutol Others Segmentation by application Hospital Pharmacy Clinics Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Aventis Pharmaceuticals Sanofi -Aventis Versapharma Incorporated Sigma Pharmaceutical Pty Novartis AG Hoffmann-La Roche Bayer Health Care
1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Tuberculosis Therapeutics Market Size 2018-2029 2.1
